Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) – Regulatory Focus

Posted: May 18, 2017 at 2:31 pm

Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) Posted 18 May 2017 By Zachary Brennan

Welcome to Regulatory Recon, a daily regulatory news and intelligence briefing.

In Focus: US

In Focus: International

Pharmaceuticals and Biotechnology

Pharmaceuticals and Biotechnology: Study Results, Filings and Designations

Medical Devices

US: Assorted and Government

Upcoming Meetings and Events

General Health and Other Interesting Articles

Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Send him an email atnews@raps.org. A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Share this article:

Categories: Biologics and biotechnology, Drugs, Medical Devices, US, Canada, Europe, FDA, Health Canada

Tags: ASCO, Regulatory Reconnaissance, Regulatory, Links, News, Regulatory News, Regulatory Intelligence, FDA News, EMA News

Read more:

Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) - Regulatory Focus

Related Posts